CLYM — Climb Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $313.36m
- $212.28m
Annual cashflow statement for Climb Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -47.5 | -45.2 | -35.1 | -73.9 | -59.9 |
| Depreciation | |||||
| Non-Cash Items | 15.6 | 7.67 | 10.8 | 56.6 | 6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.17 | 0.21 | 3.76 | 1.7 | -0.601 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36.1 | -37.4 | -20.6 | -15.6 | -54.4 |
| Capital Expenditures | — | — | — | -4.64 | -0.186 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -115 | 34.4 | 69 | -116 | 3.02 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -115 | 34.4 | 69 | -121 | 2.83 |
| Financing Cash Flow Items | — | — | — | — | -0.086 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 177 | 0 | 0.841 | 131 | -0.021 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.4 | -3.34 | 49.5 | -5.88 | -51.5 |